← Leaderboards
Paolo Ruggerone
University Of Oklahoma
$1,146,424
Attributed
$5,732,122
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,732,122 · 1
By mechanism
R01$5,732,122 · 1
Top collaborators
- Sandrasegaram Gnanakaran5 shared
- Valentin V Rybenkov5 shared
- John K. Walker5 shared
- Helen I. Zgurskaya5 shared
Most similar at University Of Oklahoma
Same institution · by research overlap
- Sandrasegaram Gnanakaran$2,954,902
- Zhibo Yang$2,101,051
- Laura-Isobel McCall$3,552,176
- Shanteri Singh$1,999,240
- Adam Scott Duerfeldt$4,414,399
Others in their field
Other Emerging Leaders on “Anti-Bacterial Agents”
- Bruce Blough · Research Triangle Institute$19,637,160
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$11,832,144
- Denis Marc Daigle · Venatorx Pharmaceuticals, Inc.$7,512,530
- Terry Roemer · Prokaryotics, Inc.$5,750,688
- Tobias Doerr · Cornell University$3,917,047
- Berthony Deslouches · University Of Pittsburgh At Pittsburgh$3,597,192
Research focus
Anti-Bacterial AgentsAntibiotic ResistanceAntibiotic EffluxAntibiotic TherapyAreaBacteriaAntibioticsBiochemistryBiophysicsCell EnvelopeCellsClinicClinical InvestigationCommunicable DiseasesComputational BiologyBaseComputer SimulationDiffusionDrug EffluxDrug ModelingsEfflux PumpExperimental AnalysisFailureFamily
Grant awards (5)
Optimization of efflux avoidance and inhibition for antibiotic development$1,099,291
R01 · FY2022 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,106,111
R01 · FY2021 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,048,793
R01 · FY2020 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,056,326
R01 · FY2019 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,421,601
R01 · FY2018 · AI